Navigation Links
FFF Enterprises Selects A10 Networks' AX Series Advanced Traffic Manager
Date:4/25/2008

AX Series Delivers MyFluVaccine Portal a Next-generation Server Load

Balancer Platform for Web Application Delivery

SAN JOSE, Calif., April 25 /PRNewswire/ -- A10 Networks(R) today announced that FFF Enterprises, the nation's largest distributor of plasma products, vaccines and other biopharmaceuticals, selected and deployed A10's AX Series Advanced Traffic Manager to provide a Web application delivery platform for its MyFluVaccine(TM) portal. MyFluVaccine,(TM) delivered by FFF Enterprises, is the nation's first online vaccine portal, allowing vaccine providers to order a dedicated supply of vaccines for guaranteed delivery on the dates they choose. FFF Enterprises selected A10's AX Series to load balance its Web servers, especially during peak usage conditions, to ensure the MyFluVaccine portal is always available and performing as desired for its customers.

To prepare for the peak flu vaccine ordering season, FFF enterprises began evaluating Juniper's DX line of server load balancers. However, shortly after the initial evaluation, Juniper announced it will end of life its DX family with a smooth transition for customers. FFF Enterprises concurrently read about A10's AX Series Advanced Traffic Manager family in the news, highlighting recent independent third-party performance tests from the Tolly Group, which proved that AX delivers over double the performance at less than half the price of incumbents. As a result, FFF Enterprises chose to evaluate the AX Series.

"We found the AX Series at the perfect time. After reading positive stories about its price/performance advantage over incumbents we tested the AX in our environment and discovered that the claims we read were true," said Bob Coates, VP of Technology for FFF Enterprises. "A10's AX Series provides us with a high-performance server load balancer solution to ensure MyFluVaccine(TM) is always performing and available."

The key AX Series features that FFF Ente
'/>"/>

SOURCE A10 Networks
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Medsphere & Keane Join Forces to Provide Healthcare Enterprises With Integrated Electronic Health Record & Revenue Cycle Management Systems
2. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
3. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
4. Varian Medical Systems Acquires Pan-Pacific Enterprises for Marketing, Sales and Distribution of X-Ray Imaging Products in China
5. CJPS Enterprises Spins Off New Company for Intellectual Property Marketing
6. Nu Skin Enterprises Announces Increase in Quarterly Dividend
7. Harris Corporation Demonstrates Digital Signage(TM) Solutions for Dynamic, Rapid Communications within Healthcare Enterprises
8. Nu Skin Enterprises to Present at Bank of America 2008 Consumer Conference
9. CJPS Enterprises to Expand Efforts of 21st Century Jobs Fund Life Sciences Pipeline
10. Nu Skin Enterprises to Announce First Quarter 2008 Results
11. CJPS Enterprises Announces a Series of Seminars on Automotive Diversification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Though the number of jobs created ...l companies reported a different kind of slowdown:...us months. , Seattle, WA ... created in the medical field slowed in June overa...kind of slowdown that will be music to the ears of...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begins -...-- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a l... today that its subsidiary has commenced commercia...les USP product in the 40mg,strength from its Davi...with the launch, Watson has 180 days of marketing ...
(Date:7/25/2008)...BURG, Ill., July 25 /PRNewswire/ -- Sagent Pharmac...eutical company, today announced that it,has launc...iarrhythmic,indicated for the treatment and prophy...tion and hemodynamically unstable ventricular,tach...r heart beat.,Sagent,s amiodarone HCl injection wi...
(Date:7/25/2008)...AD, Calif., July 25 /PRNewswire/ -- AutoGenomics, ...ion statement on Form S-1 with the,Securities and ...al public,offering of shares of its common stock. ..., all of which are expected to be offered by,AutoG...g, have not yet been,determined., J.P. Morgan Sec...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...s of energy loss during aerobic exercises and this...w our bodies react to exercise programs is genetic...cising like the level of blood glucose in the body...publishing the works of scientists from Washington...
...dies, a part of the Zydus group, has launched Flud...onic lymphocytic leukemia. Chronic Lymphocytic Leu...a serious, progressive disease, which at present h...very uncommon in young people and becomes progress...
...s that the smokers may differ in their cravings// ... to smoking. Researchers have found that the urge ... smokers according to the brain responses to the s...e University Medical Center had looked into the br...
...nts to produce vaccines and other treatments for m...nd they hope to start clinical trials by the year ...will be of greatest benefit to developing nations ...very poor at the same time keeping in mind that hu...
Other Medicine News:Health News:Producing Vaccines from genetically modified crops 2
(Date:7/22/2008)...pment Initiative bring MJFF,s,current active indus...,2009, NEW YORK, July 22 /PRNewswire-USNewswire/...ansformative treatments and a cure for Parkinson,s...son,s Research has awarded,$2.7 million in total f...were granted under MJFF,s Therapeutics Development...
(Date:7/22/2008)...acy of Treating Patients with ...GIN-SI, South Korea, July 22 /-,Jenne... and its South,Korean partner Green Cross Corp., a...clinical trial of its first-in-class lead product ...rated and resulted in clear,anti-cancer efficacy i...
(Date:7/22/2008)...dra(R) Resulted in Significant, Reductions in A1C ...orithm Used, BRI...om the "Adjust to,Target in Type 2 Diabetes: Compa...ng for Adjustment of Mealtime Insulin Glulisine" s...ciation,s (ADA) medical journal,Diabetes Care. Th...
(Date:7/22/2008)...RNewswire/ -- Hyperion,Therapeutics, Inc. today an...n its Phase 1/2 clinical trial to evaluate the saf...f HPN-100 (formally called GT4P) versus,BUPHENYL(R...cle disorders,(UCD). The company plans to announce...ar., (Logo: http://www.newscom.com/cgi-bin/prnh/...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 1GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 2GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 3St Valentines Day Wishes 3A Perfume 3F Jewelry 3F Labiaplasty 3F 11886 1St Valentines Day Wishes 3A Perfume 3F Jewelry 3F Labiaplasty 3F 11886 2Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 1Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 2Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 3Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 4Pharmaxis to Apply to Market Bronchitol in Australia 3283 1Pharmaxis to Apply to Market Bronchitol in Australia 3283 2Pharmaxis to Apply to Market Bronchitol in Australia 3283 3
...n three investigational,agents (VEGF Trap, S-1 and...SCO meeting, BRIDGEWATER, N.J., May 29, 2007 /PRNe...y that a total of 375 abstracts,indicative of its ...d Annual Meeting of the American Society of Clinic... 2007). The results from key,studies involving the...
...INNOVIVE Pharmaceuticals,Inc. (OTCBB: IVPH) today...of INNO-406, an orally bioavailable dual Bcr-Abl a...r,treatment-intolerant chronic myelogenous leukemi...of Clinical Oncology Annual,Meeting. The meeting t...hicago, Illinois., Information related to the pres...
Other Medicine Technology:Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
FM Series Oxygen Flowmeters with Power Take Off, ,Options: , For security chain, add suffix S to model number. Example: FM107S. , For Canadian Color-Code, add suffix C to model number. Example: FM10
FM Style Neonatal Flowmeters (Brass Body)
...te offers innovative proficiency testing solutions...upport. As a result, API is one of the largest pro...12,000 laboratories enrolled. Here are just some o...roficiency Testing, Free CME/CMLE Credits Spons...
... for the professional ophthalmic photographer. Int... slit and background illumination, all controlled ... slit lamp joystick, as well as adaptors allowing ...nal level digital and 35 mm cameras, ensure ophtha...
Medicine Products: